Grady Jason A, Davis Elizabeth G, Kukanich Butch, Sherck Amanda B
Veterinary Medical Teaching Hospital, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA.
Am J Vet Res. 2010 Jul;71(7):831-9. doi: 10.2460/ajvr.71.7.831.
To assess pharmacokinetic and pharmacodynamic properties of dexamethasone administered PO as a solution or powder, compared with properties of dexamethasone solution administered IV, in apparently healthy horses.
6 adult horses.
Serum cortisol concentration for each horse was determined before each treatment (baseline values). Dexamethasone (0.05 mg/kg) was administered PO (in solution or powdered form) or IV (solution) to horses from which feed had or had not been withheld (unfed and fed horses, respectively). Each horse received all 6 treatments in random order at 2-week intervals; PO and IV administrations of dexamethasone were accompanied by IV or PO sham treatments, respectively. Plasma dexamethasone and serum cortisol concentrations were assessed at predetermined intervals.
Maximum plasma dexamethasone concentration after PO administration of powdered dexamethasone in unfed horses was significantly higher than the maximum plasma concentration after PO administration of dexamethasone solution in unfed or fed horses. Mean bioavailability of dexamethasone ranged from 28% to 66% but was not significantly different among horses receiving either formulation PO in the unfed or fed state. After dexamethasone treatment PO or IV, serum cortisol concentrations were significantly less than baseline at 1 to 72 hours in unfed horses and at 2 to 48 hours in fed horses.
PO or IV administration of dexamethasone resulted in suppression of cortisol secretion in unfed and fed adult horses; the magnitude of suppression did not differ among treatment groups, and serum cortisol concentrations returned to baseline after 48 to 72 hours.
评估地塞米松以溶液或粉末形式经口服给药的药代动力学和药效学特性,并与在健康马匹中静脉注射地塞米松溶液的特性进行比较。
6匹成年马。
在每次治疗前(基线值)测定每匹马的血清皮质醇浓度。将地塞米松(0.05mg/kg)以溶液或粉末形式经口服给药,或以溶液形式静脉注射给分别禁食或未禁食的马匹(分别为禁食马和非禁食马)。每匹马以随机顺序每隔2周接受所有6种治疗;口服和静脉注射地塞米松时分别伴有静脉或口服假治疗。在预定的时间间隔评估血浆地塞米松和血清皮质醇浓度。
在禁食马中,口服粉末状地塞米松后的最大血浆地塞米松浓度显著高于在禁食或非禁食马中口服地塞米松溶液后的最大血浆浓度。地塞米松的平均生物利用度范围为28%至66%,但在禁食或非禁食状态下接受任何一种口服制剂的马匹之间无显著差异。在口服或静脉注射地塞米松治疗后,禁食马在1至72小时、非禁食马在2至48小时时血清皮质醇浓度显著低于基线。
口服或静脉注射地塞米松均可抑制成年禁食和非禁食马的皮质醇分泌;各治疗组之间抑制程度无差异,血清皮质醇浓度在48至72小时后恢复至基线水平。